Study of IMC-001 for advanced tumors with high mutations
Part of Cancer clinical trials.
This trial tests an experimental drug called IMC-001 for people whose cancer has spread or is locally advanced and has a high number of genetic mutations (TMB-H). The drug aims to help the immune system fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a high number of genetic mutations (TMB-H) confirmed by a specific test.
- Your cancer must be advanced (spread to other parts of the body) and measurable on scans.
- You must be willing to provide a tumor tissue sample for central testing.
- You should be relatively active (ECOG score 0 or 1).
- You must have completed any recent cancer treatments at least 4 weeks before starting the study drug.
- You must have adequate organ function (blood, liver, kidneys) and be 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests IMC-002 in people with advanced cancers that did not respond to standard therapy. It may help by trying a new immune-targeting drug approach when other options have failed.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests a combination of two experimental drugs, IMM2510 and IMM01, in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug (MTI-301) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and shrinks tumors.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug (IM-1021) for people with advanced cancers like lymphoma or solid tumors who have run out of standard options. The drug targets a protein called ROR1, which is found on some cancer cells, and may help shrink tumors or slow their growth.
Hear when a new TMB-H trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.